Max Robotics — Global Service Robot Directory + US Certification

About

Hideyuki Akaza is a leading authority in urologic oncology, with a career-long focus on prostate cancer epidemiology, treatment, and regional disparities in Asia. He is best known for founding and chairing the Asian Prostate Cancer (A-CaP) study, a landmark, Asia-wide initiative launched in 2015 that systematically collects and analyzes real-world data on prostate cancer patients across diverse Asian populations. This work has been pivotal in clarifying how genetic, environmental, and lifestyle factors shape disease presentation and outcomes, challenging the assumption that Western treatment paradigms apply universally. His 2018 report on the third A-CaP meeting, with 12 citations, serves as a key reference for researchers seeking to understand regional variations in diagnosis and management. Beyond this, Akaza has contributed extensively to guidelines on hormonal therapy and active surveillance, and his research has influenced clinical practice across Japan and the broader Asia-Pacific region. With a publication record spanning decades and a citation count reflecting his role as a bridge between clinical research and public health, Akaza remains a vital voice in the global conversation on prostate cancer.